Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Clearmind Medicine Inc
(NQ:
CMND
)
1.660
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
1,157
Open
1.660
Bid (Size)
1.630 (3)
Ask (Size)
1.640 (1)
Prev. Close
1.660
Today's Range
1.660 - 1.660
52wk Range
0.9205 - 16.19
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Clearmind Medicine Signs an Agreement to Source Manufacturers and Distributors for its Alcohol Substitute Beverage Product
July 19, 2024
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Nasdaq Edges Lower; Morgan Stanley Earnings Top Views
July 16, 2024
Via
Benzinga
Performance
YTD
-40.29%
-40.29%
1 Month
+23.88%
+23.88%
3 Month
+37.19%
+37.19%
6 Month
+67.68%
+67.68%
1 Year
-86.99%
-86.99%
More News
Read More
Why Charles Schwab Shares Are Trading Lower By Over 7%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
July 16, 2024
Via
Benzinga
CMND Stock Earnings: Clearmind Medicine Reported Results for Q2 2024
June 17, 2024
Via
InvestorPlace
Crude Oil Down 1%; Bank of America Posts Upbeat Earnings
July 16, 2024
Via
Benzinga
Exposures
Fossil Fuels
Why Is SciSparc (SPRC) Stock Up 25% Today?
July 16, 2024
Via
InvestorPlace
Topics
Intellectual Property
Exposures
Intellectual Property
Dow Jumps 400 Points; US Retail Sales Flat For June
July 16, 2024
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Clearmind Medicine Obtains IND Approval from the FDA to Start the Phase I/IIa Clinical Trial with its Innovative Treatment for Alcoholism
July 16, 2024
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Clearmind Medicine Announces Submission of US Patent Application for Treating Metabolic Syndrome and Weight-loss
July 16, 2024
From
Clearmind Medicine Inc.
Via
GlobeNewswire
SciSparc Announces U.S. Patent Application for Treating Metabolic Syndrome and Weight Loss
July 16, 2024
From
SciSparc Ltd
Via
GlobeNewswire
Clearmind Medicine to Present Groundbreaking Research at Psychedelic Medicine – Israel 2024 Conference
July 12, 2024
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Why Psychedelic-Pharma Clearmind Medicine Stock Is Moving Higher
June 28, 2024
Via
Benzinga
Topics
Intellectual Property
Exposures
Intellectual Property
Clearmind Medicine Granted Patent Approval in Hong Kong for its Binge Behaviors Treatment
June 28, 2024
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Day Trading My Way From Red To Green
June 23, 2024
Via
Talk Markets
Clearmind Medicine Secured Exclusive Global Rights to Innovative Psychedelic Compounds for PTSD Treatment
June 20, 2024
From
Clearmind Medicine Inc.
Via
GlobeNewswire
What's Going On With Clearmind Medicine Stock Tuesday?
June 11, 2024
Via
Benzinga
Topics
Intellectual Property
Exposures
Intellectual Property
Clearmind Medicine Revolutionizes the $13 Billion NonAlcoholic Beverages Market with its Psychedelic-Based Drink
June 11, 2024
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Clearmind Medicine Advances its Proprietary Psychedelic- Based Synthetic Alcohol Beverage Product
May 10, 2024
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Why Clearmind Medicine Stock Is Moving Higher
May 07, 2024
Via
Benzinga
Topics
Intellectual Property
Exposures
Intellectual Property
Why Beyond Shares Are Trading Lower By Over 20%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
May 07, 2024
Via
Benzinga
Clearmind Medicine Secures Exclusive Global Rights to Breakthrough Psychedelic Compounds for PTSD Treatment
May 07, 2024
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Clearmind Applies to Cease Being a Reporting Issuer in Canada
April 30, 2024
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Psychedelics Headlines: Dementia Prevention, Psychological Flexibility, Ancient Romans' Trips And More
April 17, 2024
Via
Benzinga
Psyched: DEA Revisits Ban On Two Psychedelics, Farewell Russell Newcombe, Podcast Episode On Kanna & More
April 17, 2024
Via
Benzinga
Clearmind Medicine Announces Exclusive Licensing Agreement for Generation 3.0 Psychedelic Compounds for the Treatment of Mental Disorders
April 17, 2024
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
